Abstract:Abstract Background Perianal Crohn's disease(PCD) significantly impacts quality of life with poor long-term prognosis. Anti-tumor necrosis factor(anti-TNF) therapy improves fistula closure rates. However, achieving permanent closure remains challenging. Our aim is to evaluate the relation between antiTNF(infliximab (IFX) and adalimumab(ADA) serum concentrations at induction(w2 and 6), and clinical and radiological outcomes at w24 and w52 Methods We conducted a single tertiary center, retrospective, cohort study including patients with an established diagnosis of PCD treated with antiTNF because of perianal activity. Variables related to their PCD(phenotype, location, fistulas type) were collected. Regarding treatment, we collected serum levels at week 2,6,24 and 52, concomitant treatment and setons presence. We defined clinical response as the absence of drainage on physical examination and clinical remission as the absence of external fistula openings. Radiological response was defined as the absence of T2 hypersignal, gadolinium enhancement, abscess and proctitis in pelvic MRI Results 65 patients were included, baseline characteristics are in Table1. None of the demographic characteristics collected were statistically significant related to clinical or radiological response although non smokers(p=0.01), ileal(p=0.02) and non-stricturing disease(p=0.01) had statistically significant higher drug levels. Taking into account the clinical response at w52, IFX mean levels at w2 were 25.8μg/mL(SD 4.1) in non responders and 30.9μg/mL(SD 14) in responders(p=0.39). At w6 they were 17.2μg/mL(SD 12.2) and 19.4μg/mL(SD 13.8) respectively(p=0.7). ADA mean levels at w2 were 13.3μg/mL(SD 7.7) in non responders and 14μg/mL(SD 6.3) in responders(p=0.87). At w6 they were 10.1μg/mL(SD 3.3) and 12μg/mL(SD 6.1) respectively(p= 0.59). For radiological response at w52 IFX mean levels at w2 were 27μg/mL(SD 15.3) in non responders and 32.7μg/mL(SD 14.5) in responders(p=0.45). At w6 the mean levels were 15.9μg/mL(SD 6.7) and 23.7μg/mL(SD 14.8) respectively(p=0.27). In ADA group the mean levels at w2 were 14.8μg/mL(SD 7.6) in responders and only one patient did not respond. At w6 ADA mean levels were 12.3μg/mL(SD 5.9) in non responders and 12.7μg/mL(SD 6.2) in responders(p=0.94). Early response at w24 was related with a long-term response at w52, 89.9% of the patients who responded at w52, had already responded at w24. Conclusion In our study we observed that almost 90% of the patients who had an early response also responded at w52, so trying to achieve an early response should be an aim in clinical practice. Despite the limited number of patients, our study shows a trend in the relationship between higher antiTNF levels and clinical and radiological response rates

P431. Serology Panel for Prediction Relapse after Discontinuation of Infliximab in Patients with Crohn's Disease Achieving Clinical Remission

P430 Long-term Outcome of Crohn's Disease Patients Treated with Infliximab

P402 Discontinuation of Short-Term Infliximab Maintenance Therapy in Patients with Crohn's Disease: Outcomes and Risk Factors Associated with Relapse

Nomogram to Predict Primary Non-Response to Infliximab in Patients with Crohn's Disease: a Multicenter Study.

Distinct blood protein profiles associated with the risk of short-term and mid/long-term clinical relapse in patients with Crohn's disease stopping infliximab: when the remission state hides different types of residual disease activity

Evolution After Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study

FROM RESISTANCE TO RESPONSE: 52 WEEKS OF SUBCUTANEOUS INFLIXIMAB IN REFRACTORY CROHN'S DISEASE PATIENTS AFTER THE MULTIPLE TREATMENT FAILURES

P731 Relapse rate following withdrawal of anti-TNF therapy in patients with inflammatory bowel disease: A single-center experience

Su1332 Long-Term Outcome of Patients with Crohn's Disease in Deep Remission: C-Reactive Protein Normalization Predicting Better Outcomes

P921 Maintenance of clinical, biochemical and transmural remission in inflammatory bowel disease patients switching from intravenous to subcutaneous infliximab

External validation of serum biomarkers predicting short-term and mid/long-term relapse in patients with Crohn's disease stopping infliximab

P1058 Safety and effectiveness of subcutaneous infliximab formulation in difficult-to-treat Crohn’s Disease patients with previous exposure to intravenous infliximab: A case-series

P431 Long-term Efficacy of Maintenance Therapy with Thiopurines in Crohn's Disease

P611 Relation between AntiTNF levels during the induction and clinical and radiological outcomes in perianal Crohn ́s disease

P1049 Effectiveness and safety of subcutaneous infliximab in Crohn’s disease patients with immunogenic failure of intravenous infliximab

A Novel Model Based on Serum Biomarkers to Predict Primary Non-Response to Infliximab in Crohn's Disease

P1086 Re-administration of infliximab in patients with extremely refractory perianal Crohn’s disease

P903 Persistence, efficacy and tolerance of subcutaneous Infliximab after switch from intravenous infliximab in IBD patients in remission: one-year results from a multicenter prospective cohort

P1080 Real-world Study on Early Predictors of Infliximab Treatment Efficacy in Crohn's disease

Improvement of Psychological Status after Infliximab Treatment in Patients with Newly Diagnosed Crohn’s Disease

Infliximab is an effective option in patients with ulcerative colitis previously exposed to full subcutaneous anti-TNF agent: Results from a real-world multicenter study